Financial Data and Key Metrics Changes - The company reported adjusted net investment income of $0.58 per share, with an annualized return on equity of 13.5%, and adjusted net income of $0.36 per share, with an annualized return on equity of 8.3% for Q1 2025 [9] - Total investments decreased to $3.4 billion from $3.5 billion in the prior quarter due to net repayment activity [29] - The weighted average yield on debt and income-producing securities decreased slightly from 12.5% to 12.3% quarter over quarter [22] Business Line Data and Key Metrics Changes - In Q1, the company provided total commitments of $154 million and total funding of $137 million across six new portfolio companies and upsizes to four existing investments [15] - The company experienced $270 million of repayments from seven full and four partial investment realizations, resulting in $133 million of net repayment activity [15] - 89% of total funding this quarter was into new investments, with 11% supporting upsizes to existing portfolio companies [19] Market Data and Key Metrics Changes - The supply and demand dynamics in the US direct lending market have been characterized by an imbalance, with the supply of capital outpacing demand [14] - The company anticipates that current uncertainty and volatility will moderate the supply and demand imbalance by slowing inflows into non-traded vehicles [15] - The weighted average spread over reference rate of new investment commitments in Q1 was 700 basis points, compared to 541 basis points for public BDC peers in Q4 [23] Company Strategy and Development Direction - The company aims to remain highly selective and disciplined in capital allocation, focusing on risk-adjusted returns [16] - The company believes that periods of heightened volatility often present the most attractive investment opportunities and is well-positioned with significant liquidity [12] - The company has a disciplined capital allocation strategy, with a focus on maintaining higher portfolio yields than sector averages [11] Management's Comments on Operating Environment and Future Outlook - Management believes the business remains well protected on the asset side with limited direct exposure to tariffs and is positioned well on the liability side [8] - The company anticipates a quarterly earnings power of approximately $0.50 per share, with potential upside if activity-based fees return to historical averages [10] - Management expressed confidence in the portfolio's credit quality, with non-accruals representing only 1.2% of the portfolio at fair value [24] Other Important Information - The board approved a base quarterly dividend of $0.46 per share and a supplemental dividend of $0.06 per share [12] - The company has approximately $1 billion of unfunded revolver capacity against $175 million of unfunded portfolio company commitments [31] - The company has entered an ATM program to expand its capital raising toolkit, with no shares issued to date [32] Q&A Session Summary Question: Impact of downward pressure on spreads due to non-traded BDC fundraising - Management noted that retail flows have likely slowed due to market volatility and emphasized their resilience through a diversified capital allocation strategy [41][44] Question: Pricing risk in a volatile environment - Management indicated that the private markets are not effectively pricing risk, but their deep fundamental investment approach allows them to navigate volatility [55][58] Question: Outlook for lane two and lane three investments - Management expects to see more opportunities as stress increases in the market, particularly in the broadly syndicated loan market [81][84] Question: Impact of banks going risk-off on the liability side - Management expressed confidence in their balance sheet management and noted that recent amendments and issuances have strengthened their position [100][102]

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Ma ...

LOS ANGELES, April 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sarepta admitted on March 18, 2025, that a young patient with Duchenne ...

Financial Data and Key Metrics Changes - For Q4 2024, the company reported total revenues of $658.4 million, an increase of $261.6 million compared to $396.8 million in Q4 2023 [64] - Net product revenue for Q4 2024 was $638 million, growing 75% year-over-year, and full-year net product revenue was $1.8 billion, representing a 56% increase [14][64] - The company achieved a GAAP net income of $159 million for Q4 2024, compared to $45.7 million in Q4 2023, and a non-GAAP net income of $206 million, up from $86.6 million [67] Business Line Data and Key Metrics Changes - ELEVIDYS sales for Q4 2024 were $384.2 million, a 112% increase from the previous quarter, and total sales since approval exceeded $1 billion [15][28] - The PMO franchise generated $254 million in Q4 2024, growing approximately 9% compared to Q4 2023, with individual revenues of $137.6 million for EXONDYS 51, $40.2 million for VYONDYS 53, and $76.2 million for AMONDYS 45 [31][32] Market Data and Key Metrics Changes - The company noted that ELEVIDYS has only treated about 5% of the on-label addressable patient population, indicating significant growth potential ahead [33][114] - The PMO franchise continues to perform well, growing organically without price increases, reflecting an increase in patients served in the Duchenne community [30] Company Strategy and Development Direction - The company aims to build on the success of Project Moonshot, focusing on expanding its gene therapy pipeline and achieving multiple potential blockbuster siRNA launches by the end of the decade [9][13] - The strategic collaboration with Arrowhead is expected to diversify the company's future, adding a broad platform of siRNA programs across various therapeutic areas [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2025 net product revenue guidance of $2.9 billion to $3.1 billion, representing approximately 70% growth over 2024 [42] - The company anticipates continued growth quarter-over-quarter throughout 2025, driven by the strong performance of ELEVIDYS and the PMO franchise [81] Other Important Information - The company plans to transition to suspension manufacturing to improve cost of goods sold (COGS) and has several significant milestones expected in 2025 [20][21] - The company has approximately $1.5 billion in cash and investments as of December 31, 2024, and secured a $600 million revolving credit facility [72][73] Q&A Session Summary Question: What is the cadence of patient onboarding in Q1? - Management reiterated confidence in guidance for 2025, expecting growth quarter-over-quarter as the launch ramps up [80] Question: What is the prevalence of limb-girdle muscular dystrophy type 2E? - Management indicated that type 2E is an ultra-rare disease, with a 50-50 split between ambulatory and non-ambulatory patients [85][87] Question: Will the upcoming data for FSHD and DM1 be conclusive? - Management emphasized the importance of early data as proof of biology, with expectations for safety and efficacy signals [108][110] Question: What is the status of ELEVIDYS and PMO reinvestment? - Management noted early days for drawing conclusions on reinvestment but indicated some instances of reimbursement for both therapies [116] Question: What is the timeframe for the $500 million share repurchase program? - The program has an 18-month timeframe, with plans to be opportunistic in deploying capital as cash reserves are built back up [124]

Financial Data and Key Metrics Changes - The net loss for Q1 2025 was $173.1 million, or $1.39 per share, compared to a net loss of $132.9 million, or $1.24 per share, in Q1 2024 [45] - Revenue for Q1 2025 was $2.5 million, down from $3.6 million in Q1 2024, primarily due to changes in collaboration agreements [46] - Total operating expenses increased to $163.9 million in Q1 2025 from $140.1 million in Q1 2024, driven by higher candidate costs and salaries [46][47] - Cash and investments totaled $552.9 million at the end of Q1 2025, with a pro forma cash balance of $1.4 billion including upcoming payments from Sarepta [47][48] Business Line Data and Key Metrics Changes - The company closed a significant collaboration agreement with Sarepta Therapeutics, expecting a total of $1.375 billion in cash payments, including an upfront payment of $500 million [5][7] - The first commercial launch of Plazasiran is anticipated to drive substantial growth, with potential annual sales of $2 billion to $3 billion in the severe hypertriglyceridemia market [10][21] - The obesity pipeline includes two early-stage programs, ARO INHBE and ARO ALK7, which are expected to provide clarity on their roles in obesity treatment [11][12] Market Data and Key Metrics Changes - The FDA accepted the NDA for Plazasiran for the treatment of familial chylomicronemia syndrome (FCS), with a PDUFA action date set for November 18, 2025 [21][26] - The company is actively working on global regulatory submissions for Plazasiran and anticipates launching in the U.S. and potentially the EU [49][80] Company Strategy and Development Direction - The company aims to build a growing cardiometabolic pipeline, focusing on obesity and CNS programs, while also exploring non-core assets for potential partnerships [15][17] - The collaboration with Sarepta is seen as a critical step to balance the business model and reduce R&D expenses as Sarepta assumes clinical development responsibilities [8][9] - The company plans to expand its cardiometabolic presence with new candidates targeting APOC3 and PCSK9 [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential driven by internal development activities, particularly in Plazasiran, obesity treatments, and CNS pipeline [8][14] - The company is well-funded into 2028, allowing for multiple commercial launches and continued development of its pipeline [48] - Management highlighted the importance of educating physicians and patients about new treatment options in previously untreatable diseases [88] Other Important Information - The company is on track to complete enrollment for several Phase III studies by the end of 2025, which would enable study completion in 2026 [29][49] - The company anticipates initial data readouts from various programs, including obesity and CNS candidates, later in 2025 [49] Q&A Session Summary Question: Can you discuss the obesity programs ARO INHBE and ARO ALK7? - Management indicated that both programs are being studied as monotherapy and in combination with existing therapies, with no specific bogey set for data [54][55] Question: What is the competitive positioning of Plazasiran relative to other treatments? - Management highlighted Plazasiran's significant triglyceride reduction and its potential to achieve guideline-directed risk thresholds for patients with FCS as key differentiators [84][86] Question: What are the plans for commercialization in Europe? - The company is planning for commercialization in European markets alongside a commercial partner, with more details to be provided in the future [78]

Summary of Sarepta Therapeutics, Inc. Conference Call Company Overview - **Company**: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - **Industry**: Biotechnology, specifically focusing on therapies for Duchenne muscular dystrophy (DMD) Key Highlights 1. **Progress on SRP-5051**: The company is ahead of schedule in its clinical trials, aiming to dose the first patient in Q4 2021, earlier than initially planned [2][3] 2. **MOMENTUM Trial**: The pivotal trial for accelerated approval is referred to as Part B of the MOMENTUM study, with promising initial data showing significant exon skipping and dystrophin production compared to existing therapies [4][5] 3. **Dystrophin Production**: Initial results indicated an exon skipping rate 18 times greater than eteplirsen, with a projected dystrophin level exceeding 10% after one year of treatment [4][5][16] 4. **FDA Interaction**: The company has established a positive relationship with the FDA's Neurology division, which has experience with DMD, and has received guidance on using dystrophin as a surrogate endpoint for accelerated approval [7][9] 5. **Safety Profile**: Concerns regarding hypomagnesemia have been addressed, with the company confident that it can be managed through oral supplements [18][20] 6. **PPMO Platform**: The PPMO technology has the potential to treat approximately 80% of DMD patients, with ongoing efforts to develop therapies for rare mutations [26][39] 7. **Gene Therapy Synergy**: The company is exploring the potential for synergistic effects between its PPMO platform and gene therapy, SRP-9001, to provide comprehensive treatment options for DMD [28][29] 8. **Competitive Advantage**: Sarepta claims to have unique results in human trials with its PMO and PPMO therapies, setting it apart from competitors [32][34] Additional Insights 1. **Patient Compliance**: The company reports a compliance rate of over 90% for its therapies, indicating strong patient adherence despite the challenges posed by the pandemic [13] 2. **Future Directions**: The company plans to expand its research into other neuromuscular diseases and is focused on developing additional constructs for other skip amenable mutations [39][38] 3. **Upcoming Trials**: The company is preparing for the launch of the 301 study, which will be a double-blind, placebo-controlled trial with a primary endpoint of functional output [48][50] This summary encapsulates the key points discussed during the conference call, highlighting the company's advancements, regulatory interactions, and future plans in the biotechnology sector focused on DMD.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bank of America Securities 2021 Napa BioPharma Virtual Conference June 16, 2021 10:30 AM ET Company Participants Doug Ingram - President and CEO Ian Estepan Stan - CFO Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Tazeen Ahmad Okay. Good morning, everybody. Thanks for joining us at the Bank of America Virtual Napa Conference. It's my pleasure this morning to have with us Sarepta as our next presenting company. For the next 50 minutes, I ha ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) MOMENTUM Multiple-Ascending Dose Study of SRP-5051 for Duchenne Muscular Dystrophy Conference Call December 7, 2020 8:30 AM ET Company Participants Doug Ingram - President and Chief Executive Officer Gilmore O’Neill - Executive Vice President, R&D Conference Call Participants Salveen Richter - Goldman Sachs Tazeen Ahmad - Bank of America Gena Wang - Barclays Alethia Young - Cantor Brian Skorney - Baird Anupam Rama - JPMorgan Matthew Harrison - Morgan Stanley Tyler Va ...